据悉，康方生物的曼多奇单抗是其进入上市申报阶段的第四款非肿瘤药物，此前PCSK9单抗伊努西单 抗、IL-12/IL-23单抗依若奇单抗、IL-17A单抗古莫奇单抗已相继获批或申报上市，构建了覆盖心血管代 谢、皮肤、关节等多领域的自免产品矩阵。 智通财经APP获悉，康方生物(09926)早盘涨近5%，截至发稿，涨4.22%，报106.2港元，成交额4.56亿港 元。 消息面上，2月25日，康方生物自主研发的IL-4Rα单抗(曼多奇单抗，AK120)已正式向国家药品监督管 理局(NMPA)提交上市申请(NDA)并获受理，拟用于治疗中重度特应性皮炎(AD)。 ...

创新药龙头重磅业绩利好！百济神州2月26日发布2025年度业绩快报，全年营收382.05亿元，同比增 40.4%；归母净利润14.22亿元，实现扭亏为盈。 值得一提的是，这是这家创新药龙头公司首次实现年度盈利，也是中国创新药企全球化发展的重要里程 碑。 公告显示，百济神州业绩增长得益于核心产品放量，2025年百悦泽全球销售额280.67亿元，同比增长 48.8%。此外，公司多款候选药物进入临床关键阶段，百悦达在中国获批上市，BGB-B2033获FDA快速 通道资格认定。 开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调两个季度，长期看，较多优质标的估值性价比 明显，当前位置建议加大关注。* 低位埋伏创新药机遇，借道ETF效率更高！ 投纯正创新药，认准T+0利器——港股通创新药ETF（520880）及其场外联接基金（025221），100%布 局创新药研发类公司，前十大权重股占比超七成，龙头属性突出。 降低波动 | 项目 | 本报告期 | 上年同期 | 增减变动幅度(%) | | --- | --- | --- ...

Core Insights - The introduction of PD-1 inhibitors in 2014 marked a significant turning point in the fight against cancer, with Bristol-Myers Squibb's Opdivo and Merck's Keytruda leading the charge in immunotherapy [1][3] - The competition between Opdivo and Keytruda has evolved over the years, with Keytruda ultimately becoming the top-selling drug globally by 2024 [21][22] Historical Context - The history of cancer immunotherapy began with William Coley's discovery in the late 19th century, which was followed by a long period of stagnation until the late 20th century when key immune cells were identified [4] - The discoveries of James Allison and Tasuku Honjo regarding CTLA-4 and PD-1, respectively, laid the groundwork for the development of PD-1 inhibitors [5][10] Drug Development - Opdivo was developed with strong backing from Bristol-Myers Squibb after acquiring Medarex in 2009, leading to its approval in Japan in 2014 [12] - Keytruda's development faced initial setbacks but was revitalized by Merck's strategic decision to conduct an unprecedented "super I phase" trial, leading to its approval shortly after Opdivo [14][15][16] Market Dynamics - In 2016, a critical competition occurred between Opdivo and Keytruda in the non-small cell lung cancer (NSCLC) market, which is the largest segment in oncology [17] - BMS's failure in the CheckMate-026 trial led to a significant drop in Opdivo's market position, while Merck's more selective approach in the KEYNOTE-024 trial resulted in Keytruda's success [18][19][20] Sales Performance - By 2024, Keytruda's sales reached $29.5 billion, marking an 18% increase and solidifying its position as the top-selling drug globally [21] - Opdivo, while still a major player, saw its sales decline but remained above the $10 billion mark, maintaining its status as a heavyweight in the market [22][23] Competitive Landscape - The global PD-1 inhibitor market is highly competitive, with 527 candidates in development as of early 2025, including 20 approved drugs [26][29] - In China, the market is characterized by intense competition among local manufacturers, with significant price reductions due to national healthcare negotiations [30][31] Future Outlook - Keytruda's core patent is expected to expire in 2028, potentially leading to a significant drop in sales as biosimilars enter the market [32] - A new challenger, Ivonescimab, has shown superior efficacy compared to Keytruda in clinical trials, indicating a shift towards dual-target therapies in cancer treatment [33][35]

写在文章前的声明：在本文之前的说明：本文中所列的投资信息，只是一个对基金资产净值进行排行的客观描述，并无主观倾向性，也不是投资建议，纯属 娱乐性质。 一顿操作猛如虎，基金净值已更新，谁是基金中的王者，谁又垫底，请看数据： | 基金简称 PK | | | YANNEWSGH FRANCE AND | | | --- | --- | --- | --- | --- | | 1 | 华泰柏瑞中 ... C | 2.7528 | 6.04% | 8 | | | 019455 | 2026-2-26 | | | | 2 | 华泰柏瑞中 ... A | 2.7691 | 6.03% | 8 | | | 019454 | 2026-2-26 | | | | 3 | 华泰柏瑞中韩 ... l | 2.7662 | 6.03% | 8 | | | 022681 | 2026-2-26 | | | | 4 | 广发利鑫混合C | 3.0650 | 5.44% | | | | 011172 | 2026-2-26 | | | | 5 | 广发利鑫混合A | 3.1270 | 5.43% | 8 | | | 002446 | 202 ...

由于与辉瑞达成合作，三生国健（688336.SH）2025年业绩大涨。根据公司发布的业绩快报，2025年三生国建实现营业收入41.99亿元，较上年增加 251.81%；实现归母净利润29.39亿元，较上年涨幅317.09%。 同时，扣除本年度确认的政府补助收益、理财产品利息收入、固定资产处置损失、参股公司分红收益及营业外支出后，实现扣非净利润28.05亿元，涨幅 1041.01%。 三生国健在业绩快报中指出，营业总收入、归母净利润、扣非净利润、基本每股收益、总资产等指标相比上年同期均出现较大幅度增长，主要由于报告期内 公司与辉瑞公司（Pfizer Inc.）达成重要合作，公司收到辉瑞公司就707项目支付的授权许可首付款并相应确认收入约28.90亿元。 2025年5月20日，三生国健的母公司三生制药（01530.HK）与辉瑞关于PD-1/VEGF双特异性抗体SSGJ-707的交易发布，此次交易达成12.5亿美元不可退还且 不可抵扣的首付款。 在达成重磅交易的同时，三生国健或将面临PD-1/VEGF双抗赛道日趋激烈的市场竞争。作为近年来备受瞩目的明星靶点，该赛道入局者众多、竞争激烈。 Insight数据库显示，目 ...

由于与辉瑞达成合作，三生国健（688336.SH）2025年业绩大涨。根据公司发布的业绩快报，2025年三 生国建实现营业收入41.99亿元，较上年增加251.81%；实现归母净利润29.39亿元，较上年涨幅 317.09%。 同时，扣除本年度确认的政府补助收益、理财产品利息收入、固定资产处置损失、参股公司分红收益及 营业外支出后，实现扣非净利润28.05亿元，涨幅1041.01%。 三生国健在业绩快报中指出，营业总收入、归母净利润、扣非净利润、基本每股收益、总资产等指标相 比上年同期均出现较大幅度增长，主要由于报告期内公司与辉瑞公司（Pfizer Inc.）达成重要合作，公 司收到辉瑞公司就707项目支付的授权许可首付款并相应确认收入约28.90亿元。 2025年5月20日，三生国健的母公司三生制药（01530.HK）与辉瑞关于PD-1/VEGF双特异性抗体SSGJ- 707的交易发布，此次交易达成12.5亿美元不可退还且不可抵扣的首付款。 在达成重磅交易的同时，三生国健或将面临PD-1/VEGF双抗赛道日趋激烈的市场竞争。作为近年来备受 瞩目的明星靶点，该赛道入局者众多、竞争激烈。 Insight数据库显 ...

摘要 ■ 投资逻辑 基于大模型对券商年度展望的全面解析 每年的年底到年初，各券商会密集发布关于总量、行业等年度报告。对投资者而言，难以整合大量研报信息从而提取共识点，此外分歧点也同样缺乏量化 对比。大模型工具的出现解决了这一难点，大模型可以帮助分析师快速完成研报数据预处理、观点精准抓取与分类；大模型通过确定共识点与分歧点的判 定规则，系统整合分散观点，量化呈现各券商对板块不同观点的支持率，清晰核心分歧维度。本次研究以大模型为核心分析工具，全面剖析2026年各大板 块年度展望，梳理宏观、策略、固收及七大细分行业的共识与分歧，为投资者提供高效精准的决策参考。 总量观点总结 对于总量观点，我们分别从宏观经济、年度策略、固定收益三个方面分别剖析了各券商分析师的年度展望。 在宏观经济方面，大多数券商认为随着"十五五"政策发力，2026年GDP目标为5%左右；CPI、PPI从低位逐步修复，国内通货膨胀的压力得到缓解；货币 政策维持适度宽松基调，流动性保持合理充裕；财政政策延续积极取向，赤字率维持合理高位；出口保持稳健，贸易顺差维持历史较高水平；国外环境虽 然出现波动，但整体风险可控。 作者：高智威、许坤圣 在年度策略方面 ...

Group 1 - The pharmaceutical sector is experiencing significant growth, with BD transaction volumes reaching new highs and domestic innovative drugs gaining international recognition, making it a focal point for investors [1][3] - However, there is a growing fatigue regarding the expectations for innovative drugs going abroad, leading to a shift from a "highlight moment" to a "volatile adjustment" in the market [2][3] - This transition is viewed as a necessary step towards a long-term market trend, with signs of recovery in the pharmaceutical sector as it approaches a new cycle starting in 2026 [3][11] Group 2 - The current investment rationale in the pharmaceutical sector is supported by three main forces: demand, supply, and policy, which are converging to fuel a new round of growth [5][36] - Demand for healthcare is increasing due to an aging population and rising health awareness, transforming medical consumption from optional to essential [6][37] - The supply side shows that China's innovative drugs are becoming globally competitive, with the number of innovative drug pipelines accounting for nearly 30% of the global total and BD overseas licensing transactions reaching $135.7 billion in 2025, a 161% increase year-on-year [7][38] Group 3 - Policy changes are shifting from cost control to empowerment, with new measures introduced to support the entire chain of innovative drug development, access, usage, and payment [10][41] - The Hong Kong stock market is becoming a primary platform for Chinese innovative drug companies due to its flexible listing regulations and foreign investment environment, which has attracted over 70 competitive innovative drug and CXO companies [12][43] - The establishment of the Hong Kong Medical Device Regulatory Center (CMPR) and other supportive mechanisms is expected to enhance the internationalization and business development capabilities of companies listed in Hong Kong [13][44] Group 4 - The Hang Seng Biotechnology Index has outperformed other indices with a 82.75% increase, highlighting its strong market position [16][46] - The index is composed of the top 30 biotechnology companies, focusing on high-growth sectors such as innovative drugs (79% weight) and CXO services (11% weight), ensuring coverage of the core segments of the pharmaceutical industry [17][49] - The index's unique feature includes being the only pharmaceutical-themed index in Hong Kong equipped with index futures, providing risk management tools and enhancing liquidity for investors [23][54] Group 5 - The Hang Seng Biotechnology Index is currently at a historically low valuation, with a PE ratio of 30.01, significantly lower than the NASDAQ Biotechnology Index and the CSI Biotechnology Index, indicating a valuation advantage [26][55] - The index's components are primarily leading innovative drug and CXO companies with solid R&D capabilities, suggesting potential for steady profit release as pipelines mature and orders are fulfilled [28][57] - The current market conditions may present a favorable opportunity for long-term investors to allocate resources into high-quality pharmaceutical assets through the Hang Seng Biotechnology ETF [29][58]

今日（2.26），港股创新药板块回调，创新药纯度100%的港股通创新药ETF(159570)跌超1.5%，盘中成交额突破6亿元，资金逆市净流入超 1400万元！资金面上，近10日累计"吸金"超3.6亿元！最新规模超250亿元，同类规模遥遥领先！ 短期来看，2-3月有望迎来创新药企业的业绩披露窗口，多家药企有望迎来减亏或扭亏，同时预计2026年更多创新药企业有望扭亏并大幅释 放利润。展望全年，AACR（4月）、ASCO（5月）、ESMO（10月）等学术会议上国产创新药有望进一步带来临床数据的兑现。整体上， 创新药前期回调较为充分，向上产业趋势明确，催化近期密集，继续看好板块投资机会。（来源：国金证券20260207《业绩与临床数据催 化密集，看好创新药板块回暖》） 【机构盘点：2026年创新药投资三大主线】 国金证券指出，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。 据医保魔方统计，2025年中国新药License-out交易数量达158笔，总交易规模达1357亿美元，总首付款规模达70亿美元，交易数量与金额均 创近十年新高。出海BD的繁荣，一方面有 ...

Group 1 - The Hong Kong innovative drug sector experienced a downward trend, with the Hong Kong Stock Connect Innovative Drug ETF (520880) dropping over 1% in early trading on February 26 [1] - Among the constituent stocks, Jiage Ankang-B led with a gain of over 5%, while Baiji Shenzhou fell sharply by 3% [1] - The industry is seeing active external licensing transactions, with Innovent Biologics and Eli Lilly forming a global strategic partnership focused on oncology and immunology [3] Group 2 - Key pipelines are making progress overseas, with two innovative drugs from CSPC Pharmaceutical Group starting Phase III clinical trials and receiving FDA IND approval [3] - Jianghai Securities predicts that by 2026, pharmaceutical business development (BD) transactions will focus on unmet clinical needs, technological differentiation, and globalization [3] - Huachuang Securities emphasizes the transition in the innovative drug industry from quantity to quality, suggesting a focus on differentiated domestic and international pipelines by 2025 [3] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, with top ten weighted stocks including CSPC Pharmaceutical Group and Baiji Shenzhou [3]